Skip to content

Tracers of radionuclide imaging

The radiopharmaceutical used is always selected in a case-specific manner. The radioisotopes most commonly used in cancer treatments are samarium, iodine, rhenium, lutetium and yttrium. The most common tracer in the imaging of cancer is fluorodeoxyglucose (FDG). The attending doctor together with the Chief Physician of Molecular Radiotherapy & Nuclear Medicine will determine the tracer that is optimal in any given situation.

Tracers available at Docrates Cancer Center

For example, FDG is a tracer which can not only be used in diagnosing of different types of cancers, but also in assessing their response to treatments. A tracer named PSMA, instead, is utilised in the overall staging of prostate cancer, and natriumfluoride (18F-NaF) is an excellent tracer for examining tumor staging to the bones.

PSMA is particularly sensitive in identifying post-operative or post-radiotherapy recurrences of prostate cancer at very low PSA-levels, as well as the dissemination of early prostate cancer to, for example, lymph nodes. PSMA imaging enables a more accurate diagnosis of prostate cancer, which means that the treatment can be better tailored using methods such as modern radiotherapy, promoting a good quality of life. Being able to accurately locate the cancer is also very important for the surgeon, among others, when planning a prostatectomy.

In addition to prostate cancer, the focus area in tracer diagnostics at Docrates is gynaecological cancers, particularly breast cancer.

Tracer production

Cyclotron

MAP Medical Technologies operates in the same building as Docrates Cancer Center. It has a cyclotron for the manufacture of radionuclide tracers and a GMP-level laboratory. There are only a handful of cancer hospitals in the world that can so optimally take advantage of the location of a cyclotron and imaging equipment (PET-CT, SPECT-CT) under the same roof.

map-medical

Read more

Breast reconstruction surgery means meticulous craftsmanship by experienced surgeons

Reconstructing a removed breast is part of the treatment path of many breast cancer patients. The goal of the surgery...

Read more

Chief Clinical Director of Docrates Cancer Center: “Genetic information is an essential part of modern cancer care”

New forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...

Customer message 3. September, 2024

With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...

The competition authority issues its decision on the merger of Mehiläinen and Docrates Cancer Center

On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00